Pfizer adds $600M to its venture group, with a special focus on the neurosciences field it just retreated from
Pfizer $PFE may have made an abrupt exit out of the neurosciences R&D arena, but it’s still interested in backing the biotechs willing to navigate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
